Investing.com -- Phio Pharmaceuticals Corp (NASDAQ:PHIO)股价上涨26%,此前该公司宣布与一家美国制造商签订了其主要化合物PH-762的药物物质开发服务协议。 该协议涵盖PH-762的分析和工艺开发以及cGMP制造,这代表着Phio针对皮肤癌的肿瘤内治疗项目的关键进展。这家临床阶段的siRNA生物制药公司目前正在为其针对皮肤鳞状细胞癌、默克尔...
Source LinkInvesting.com -- Phio Pharmaceuticals Corp (NASDAQ:PHIO)股价上涨26%,此前该公司宣布与一家美国制造商签订了其主要化合物PH-762的药物物质开发服务协议。 该协议涵盖PH-762的分析和工艺开发以及cGMP制造,这代表着Phio针对皮肤癌的肿瘤内治疗项目的关键进展。这家临床阶段的siRNA生物制药公司目前正在为其针对皮肤鳞状细胞癌、默克尔...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.